Abstract：
BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We reviewed the clinical records of 2193 consecutive breast cancer patients who presented between January 1999 and December 2010. We explored the incidence of BM in relation to standard clinicopathological factors, and determined the cumulative risk of BM according to the disease stage and phenotype. RESULTS:Of the 2193 included women, 160 (7.3%) developed BM at a median follow-up of 5.8 years. Age younger than 60 years (P = .015), larger tumors (P = .004), lymph node (LN) positivity (P < .001), high tumor grade (P = .012), and HER2 positivity (P < .001) were associated with higher incidence of BM in the whole population. In patients who presented with locoregional disease, 3 factors independently predicted BM: large tumors (hazard ratio [HR], 3.60; 95% confidence interval [CI], 1.54-8.38; P = .003), axillary LN metastasis (HR, 4.03; 95% CI, 1.91-8.52; P < .001), and HER2 positivity (HR, 1.89; 95% CI, 1.0-3.41; P = .049). A Brain Relapse Index was formulated using those 3 factors, with 5-year cumulative incidence of BM of 19.2% in those having the 2 or 3 risk factors versus 2.5% in those with no or 1 risk factor (P < .001). In metastatic patients, 3 factors were associated with higher risk of BM: HER2 positivity (P = .007), shorter relapse-free interval (P < .001), and lung metastasis (P < .001). CONCLUSION:Disease stage and biological subtypes predict the risk for BM and subsequent treatment outcome.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Azim HA,Abdel-Malek R,Kassem Ldoi
10.1016/j.clbc.2017.08.004subject
Has Abstractpub_date
2018-04-01 00:00:00pages
e187-e195issue
2eissn
1526-8209issn
1938-0666pii
S1526-8209(17)30235-5journal_volume
18pub_type
杂志文章abstract：INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2019.08.007
更新日期：2020-02-01 00:00:00
abstract：:The 26S proteasome is an adenosine triphosphate-dependent multicatalytic protease that is responsible for most nonlysosomal intracellular protein degradation. To be selected for proteasomal degradation, proteins must be previously tagged with a polyubiquitin chain, which is then recognized by the proteasome; the ubiqu...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2004.n.020
更新日期：2004-06-01 00:00:00
abstract：:Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2000.n.010
更新日期：2000-07-01 00:00:00
abstract：BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clbc.2018.04.017
更新日期：2018-10-01 00:00:00
abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2020.03.007
更新日期：2020-08-01 00:00:00
abstract：:Bisphosphonates (BPs) are approved for preventing the skeletal-related events associated with malignant bone disease. Several studies indicate that they may also prevent cancer therapy-induced bone loss. Multiple preclinical and early clinical studies provide evidence of the anticancer activity of BPs, including an in...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2010.n.047
更新日期：2010-10-01 00:00:00
abstract：:Post-breast cancer treatment-related angiosarcomas were first observed in lymphedematous extremities after mastectomy and are now being reported with increasing frequency after lumpectomy and radiation. A case history is presented of a BRCA2 carrier who had a postmastectomy chest wall angiosarcoma but had neither ther...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2008.n.066
更新日期：2008-12-01 00:00:00
abstract：BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.06.001
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.05.007
更新日期：2020-12-01 00:00:00
abstract：BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2009.n.018
更新日期：2009-05-01 00:00:00
abstract：:For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substa...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2003.n.013
更新日期：2003-04-01 00:00:00
abstract：BACKGROUND:Luminal-type breast cancers are the most abundant subtype. Endocrine therapies targeting estrogen receptor (ER) or estradiol (E2) synthesis have achieved marked improvement in disease-free and overall survival of ER-positive cancers. However, approximately one-third of these cancers are poorly responsive to ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.11.002
更新日期：2015-04-01 00:00:00
abstract：PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.09.005
更新日期：2020-09-10 00:00:00
abstract：:Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2006.n.030
更新日期：2006-06-01 00:00:00
abstract：:[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2003.s.016
更新日期：2003-04-01 00:00:00
abstract：BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.015
更新日期：2019-04-01 00:00:00
abstract：PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.03.002
更新日期：2020-08-01 00:00:00
abstract：:Breast cancer is the most common type of cancer among women and the second leading cause of cancer death in the United States. Metastatic breast cancer is considered incurable, and treatment is aimed at palliating symptoms, achieving remission, and prolonging survival. Treatment options for metastatic disease vary bas...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2011.07.001
更新日期：2012-02-01 00:00:00
abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.09.008
更新日期：2015-04-01 00:00:00
abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2001.n.002
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2012.01.004
更新日期：2012-04-01 00:00:00
abstract：:The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2020.01.002
更新日期：2020-08-01 00:00:00
abstract：:Trastuzumab/chemotherapy combinations have already shown superior results in metastatic breast cancer patients. The purpose of this study is to determine the clinical efficacy of neoadjuvant trastuzumab and docetaxel in women with locally advanced breast cancer, with or without metastatic disease. Treatment-naive wome...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/cbc.2003.n.040
更新日期：2003-12-01 00:00:00
abstract：BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2011.n.006
更新日期：2011-03-01 00:00:00
abstract：:Neoadjuvant chemotherapy has been employed increasingly in operable breast cancer during recent years. Several randomized trials showed that the chances of breast conserving therapy are being enhanced, and that survival was not compromised by primary systemic therapy compared to adjuvant treatment. Apart from the surg...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2004.n.039
更新日期：2004-12-01 00:00:00
abstract：:More than 220,000 women will be diagnosed with breast cancer this year, and approximately 75% of these women will be long-term survivors of this disease. Survival has improved largely because of advances in adjuvant hormone therapy and chemotherapy, as well as early detection strategies. Because most women will receiv...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2007.s.003
更新日期：2007-07-01 00:00:00
abstract：BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.11.018
更新日期：2020-12-05 00:00:00
abstract：UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2011.05.001
更新日期：2011-12-01 00:00:00
abstract：BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.08.002
更新日期：2016-02-01 00:00:00
abstract：BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.11.006
更新日期：2017-06-01 00:00:00
